Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cefazolin sodium, quantity: 2.097 mg - injection, powder for - excipient ingredients: - treatment of the following serious infections due to susceptible organisms: ? respiratory tract infections due to strep. pneumoniae, klebsiella sp., h. influenzae, staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present. ? genitourinary tract infections due to e. coli, p. mirabilis, klebsiella sp. and some strains of enterobacter and enterococci. ? skin and skin structure infections due to staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci and other strains of streptococci. ? bone and joint infections due to staph. aureus. ? septicaemia due to strep. pneumoniae, staph. aureus (penicillin sensitive and penicillin resistant), p. mirabilis, e. coli and klebsiella sp. ? endocarditis due to staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. ? appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - pregabalin, quantity: 20 mg/ml - oral liquid, solution - excipient ingredients: sucralose; monobasic sodium phosphate monohydrate; purified water; methyl hydroxybenzoate; dibasic sodium phosphate; flavour - pregabalin-aft is indicated for the treatment of neuropathic pain in adults.,pregabalin-aft is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - piperacillin sodium, quantity: 4170 mg (equivalent: piperacillin, qty 4000 mg); tazobactam sodium, quantity: 540 mg (equivalent: tazobactam, qty 500 mg) - injection, powder for - excipient ingredients: nitrogen - piptaz-aft is indicated in the treatment of serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: 1. lower respiratory tract infections 2. urinary tract infections (complicated and uncomplicated) 3. intra-abdominal infections 4. skin and skin structure infections 5. bacterial septicaemia 6. gynaecological infections,children under the age of 12 years in hospitalised children aged 2 to 12 years, piptaz-aft is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years. while piptaz-aft is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing, piperacillin-resistant organisms. appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to determine their susceptibilities to piptaz-aft. therapy with piptaz-aft, however, may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above; however, once these results become available, appropriate therapy should be continued. in serious infections, presumptive therapy with piptaz-aft may be initiated before susceptibility test results are available. combination therapy with piptaz-aft and aminoglycosides may be used in the treatment of serious infections caused by pseudomonas aeruginosa. both drugs should be used in full therapeutic doses. as soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic potassium phosphate; water for injections; nitrogen - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: monobasic potassium phosphate; dibasic sodium phosphate dodecahydrate; water for injections; nitrogen - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: dibasic sodium phosphate dodecahydrate; nitrogen; water for injections; monobasic potassium phosphate - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections; monobasic potassium phosphate; dibasic sodium phosphate dodecahydrate; nitrogen - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: nitrogen; dibasic sodium phosphate dodecahydrate; monobasic potassium phosphate; water for injections - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections; nitrogen; monobasic potassium phosphate; dibasic sodium phosphate dodecahydrate - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - granisetron hydrochloride -